Altshuler Shaham Ltd Has $1.01 Million Holdings in Haleon PLC Sponsored ADR $HLN

Altshuler Shaham Ltd decreased its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 98.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 100,000 shares of the company’s stock after selling 7,838,977 shares during the period. Altshuler Shaham Ltd’s holdings in Haleon were worth $1,011,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust increased its stake in Haleon by 101.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock valued at $29,000 after buying an additional 1,433 shares during the last quarter. Stance Capital LLC purchased a new stake in Haleon in the 3rd quarter valued at about $34,000. Geneos Wealth Management Inc. grew its position in shares of Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after acquiring an additional 1,203 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Haleon by 428.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock valued at $57,000 after acquiring an additional 5,124 shares during the period. Finally, Assetmark Inc. grew its position in shares of Haleon by 26.6% during the 4th quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock valued at $60,000 after acquiring an additional 1,252 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Down 2.4%

Shares of NYSE:HLN opened at $8.88 on Thursday. The firm has a fifty day moving average price of $9.29 and a two-hundred day moving average price of $9.89. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. Haleon PLC Sponsored ADR has a one year low of $8.65 and a one year high of $11.28. The company has a market cap of $39.26 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.07 and a beta of 0.13.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The firm had revenue of $3.65 billion during the quarter. Analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on HLN shares. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Rothschild & Co Redburn downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Finally, Argus raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.